Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05024396
Other study ID # 2021-D0004
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2021
Est. completion date October 10, 2021

Study information

Verified date October 2021
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to test intratester and intertester reliability of maximum jump height using the sensor Orthelligent Pro. The secondary objective is to test the concurrent validity of maximum jump height measured with the Orthelligent Pro compared to the gold standard which is the force plate.


Description:

In everyday physiotherapy practice, there is often no budget for expensive measuring instruments. Thus, devices such as a force plate are rarely available. Physiotherapists are always looking for inexpensive, practical and portable measuring instruments to evaluate therapy outcomes and to make reliable statements about the time for Return to Sport. Maximum jump height is a performance-determining factor in various jump-intensive game sports. In addition, the jump height serves as an important criterion to decide when an athlete can return to his usual sport after an injury. There is a new sensor on the market that measures jump height. This sensor is called Orthelligent Pro. It is shown to be a cost-effective and feasible measurement method for return to sport in physical therapy practice. So far, validity and reliability has never been tested. Therefore, this study aims to test the validity and reliability of the Orthelligent Pro for the measurement of maximum jump height. Two visits will take place 1-2 weeks apart. At the first visit, participants will complete 2x3 single-leg countermovement jumps measured by two testers each. At the second visit, three jumps are completed measured by the first tester. The primary objective is to evaluate the intra-and intertester reliability of maximum jump height using Orthelligent Pro. The secondary objective is to test the concurrent validity of maximum jump height measured with the Orthelligent Pro compared with the gold standard which is the force plate. The primary and secondary endpoints are maximum jump height measured in centimeters.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date October 10, 2021
Est. primary completion date October 10, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - male and female persons aged 18-65 years - performing at least 1x / week a training including jumping elements - familiar with counter movement jumps - good knowledge of German - understand verbal and written instructions - signed informed consent Exclusion Criteria: - known pregnancy - known or suspected non-compliance with the protocol - drug or alcohol abuse - inability of the individual to follow the testing procedures, e.g., due to language problems, mental illness, dementia, etc. - injuries of the lower extremity in the past year - concomitant diseases of the foot, knee or hip - tiring activity of the lower extremity the day before the test - vigorous activity of the lower extremity one hour before the test

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
maximum jump height
Three single leg countermovement jumps were performed. The maximum jump height is measured with a sensor that is adapted at the subjects'leg and with a force plate.

Locations

Country Name City State
Switzerland Physiotherapie Occupational Therapy University Hospital Zurich Zürich

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary maximum jump height the maximum jump height will be measured in centimeters two weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1